$Recursion Pharmaceuticals(RXRX.US) It's unclear in the next three to five years, with many needing to be realized, what about the next six months? H1 2026: Cash reserves until the end of 2027, Tempus AI's data licensing fees won't issue additional shares until the end of 2026, except for any new M&A. At least in H1 2026, the Damocles sword of share issuance isn't a concern; 2026 is expected to have $100-200 million in milestone and partner payments, the new CEO may bring new collaborations, and H1 is expected to see more collaboration payments realized; the self-developed pipeline REC-617/1245 is expected to have data readouts in H1, and REC-4881 will discuss registration pathways with the FDA. Overall, there are many events in H1 2026, but it's unclear if they'll be catalysts. I believe they will, but risk control will also be managed—this is not investment advice.